RNA Disruption Indicates CHOP Therapy Efficacy in Canine Lymphoma

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2019 Dec 18

PMID 31842875

Citations 3

Authors

Amadeo M Parissenti

Laura B Pritzker

Baoqing Guo

Rashmi Narendrula

Shirly Xiaohui Wang

Lin Laura Lin

Jingchun Pei

Karolina Skowronski

Dorothee Bienzle

J Paul Woods

Kenneth P H Pritzker

Brenda L Coomber

Affiliations

Soon will be listed here.

Abstract

Background: Assessment of the efficacy of a multi-agent chemotherapy protocol in which cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are administered in canine lymphoma is generally performed by physical measurement of lymph node diameter. However, no consistent correlation has been made with prognostic indicators and the length or absence of clinical remission based on lymph node size. RNA disruption measured mid-therapy has been correlated with increased disease-free survival in recent studies of human cancer and was assessed in this study of canine lymphoma patients. Fine needle aspirate samples were taken before treatment and at weeks 3, 6, and 11 of CHOP therapy. RNA was isolated from these samples and assessed using an Agilent Bioanalyzer. RNA disruption assay (RDA) analysis was performed on the data from the resulting electropherograms.

Results: An increased RNA disruption index (RDI) score was significantly associated with improved progression-free survival.

Conclusions: Predicting the risk of early relapse during chemotherapy could benefit veterinary patients by reducing ineffective treatment and could allow veterinary oncologists to switch earlier to a more effective drug regimen.

Citing Articles

Advancing Veterinary Oncology: Next-Generation Diagnostics for Early Cancer Detection and Clinical Implementation.

Alshammari A, Oshiro T, Ungkulpasvich U, Yamaguchi J, Morishita M, Khdair S Animals (Basel). 2025; 15(3).

PMID: 39943159 PMC: 11816279. DOI: 10.3390/ani15030389.

Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.

Cazzaniga M, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos E JNCI Cancer Spectr. 2023; 8(1).

PMID: 38113421 PMC: 10765091. DOI: 10.1093/jncics/pkad107.

RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells.

Butler P, Pascheto I, Lizzi M, St-Onge R, Lanner C, Guo B Sci Rep. 2023; 13(1):1711.

PMID: 36720913 PMC: 9889758. DOI: 10.1038/s41598-023-28635-8.

Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas.

Garnica T, Lesbon J, Avila A, Rochetti A, Matiz O, Ribeiro R Sci Rep. 2020; 10(1):20371.

PMID: 33230132 PMC: 7683601. DOI: 10.1038/s41598-020-77366-7.

References

Johnston S, Thamm D, Legutki J . The immunosignature of canine lymphoma: characterization and diagnostic application. BMC Cancer. 2014; 14:657. PMC: 4168252. DOI: 10.1186/1471-2407-14-657. View

Burkhard M, Bienzle D . Making Sense of Lymphoma Diagnostics in Small Animal Patients. Clin Lab Med. 2015; 35(3):591-607. DOI: 10.1016/j.cll.2015.05.008. View

Alsharedi M, Gress T, Dotson J, Elmsherghi N, Tirona M . Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer. Med Oncol. 2016; 33(3):27. DOI: 10.1007/s12032-016-0740-1. View

Neschadim A, Pritzker L, Pritzker K, Branch D, Summerlee A, Trachtenberg J . Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts. Endocr Relat Cancer. 2014; 21(3):459-71. DOI: 10.1530/ERC-14-0088. View

Lawrence J, Vanderhoek M, Barbee D, Jeraj R, Tumas D, Vail D . Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma. Vet Radiol Ultrasound. 2009; 50(6):660-8. DOI: 10.1111/j.1740-8261.2009.01612.x. View

Siddiqui M, Mukherjee S, Manivannan P, Malathi K . RNase L Cleavage Products Promote Switch from Autophagy to Apoptosis by Caspase-Mediated Cleavage of Beclin-1. Int J Mol Sci. 2015; 16(8):17611-36. PMC: 4581211. DOI: 10.3390/ijms160817611. View

Wang S, Lee J, Liao A . Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma. Vet J. 2015; 205(1):69-73. DOI: 10.1016/j.tvjl.2015.04.032. View

Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J . The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J. 2002; 1(1):53-66. DOI: 10.1038/sj.thj.6200013. View

Narendrula R, Mispel-Beyer K, Guo B, Parissenti A, Pritzker L, Pritzker K . RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. BMC Cancer. 2016; 16:146. PMC: 4765116. DOI: 10.1186/s12885-016-2197-1. View

10.

Lawrence J, Cameron D, Argyle D . Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1673). PMC: 4581034. DOI: 10.1098/rstb.2014.0233. View

11.

Deravi N, Berke O, Woods J, Bienzle D . Specific immunotypes of canine T cell lymphoma are associated with different outcomes. Vet Immunol Immunopathol. 2017; 191:5-13. DOI: 10.1016/j.vetimm.2017.07.008. View

12.

Zandvliet M . Canine lymphoma: a review. Vet Q. 2016; 36(2):76-104. DOI: 10.1080/01652176.2016.1152633. View

13.

Rassnick K, Bailey D, Malone E, Intile J, Kiselow M, Flory A . Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. Vet Comp Oncol. 2010; 8(4):243-53. DOI: 10.1111/j.1476-5829.2010.00224.x. View

14.

Parissenti A, Chapman J, Kahn H, Guo B, Han L, OBrien P . Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2009; 119(2):347-56. DOI: 10.1007/s10549-009-0531-x. View

15.

Wen F, Zhou R, Shen A, Choi A, Uribe D, Shi J . The tumor suppressive role of eIF3f and its function in translation inhibition and rRNA degradation. PLoS One. 2012; 7(3):e34194. PMC: 3311619. DOI: 10.1371/journal.pone.0034194. View

16.

Toomey S, Eustace A, Pritzker L, Pritzker K, Fay J, OGrady A . RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Natl Cancer Inst. 2016; 108(8). PMC: 5017949. DOI: 10.1093/jnci/djw111. View

17.

LeBlanc A, Jakoby B, Townsend D, Daniel G . 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Radiol Ultrasound. 2009; 50(2):215-23. DOI: 10.1111/j.1740-8261.2009.01520.x. View

18.

Fontaine S, McCulloch E, Eckersall P, Haining H, Patterson Kane J, Morris J . Evaluation of the modified Glasgow Prognostic Score to predict outcome in dogs with newly diagnosed lymphoma. Vet Comp Oncol. 2017; 15(4):1513-1526. DOI: 10.1111/vco.12296. View

19.

Parissenti A, Guo B, Pritzker L, Pritzker K, Wang X, Zhu M . Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy. Breast Cancer Res Treat. 2015; 153(1):135-44. DOI: 10.1007/s10549-015-3498-9. View

20.

Mudaliar M, Haggart R, Miele G, Sellar G, Tan K, Goodlad J . Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS One. 2013; 8(9):e72591. PMC: 3762807. DOI: 10.1371/journal.pone.0072591. View